$KYTX
Kyverna Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$7.20
▲+2.27%+$0.160
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateKyverna Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is KYTX up today? It is at $7.20 (+2.27%), and our scanner flagged it 64 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KYTX spikes, and full due diligence on KYTX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $KYTX 64 times in the last 30 days. Create a free account to track $KYTX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on KYTX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KYTX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Aktar Mert Director | Acquired (grant/award) | +5K | added 31% | 22K | n/a | May 27, 26 |
Shaw Christi Officer | Sold (automatic/other) | -4K | sold 5.9% | 67K | $36K at $8.59 | May 27, 26 |
Seidenberg Beth C Director | Acquired (grant/award) | +5K | added 31% | 22K | n/a | May 27, 26 |
Cohen Fred E Director | Acquired (grant/award) | +5K | added 31% | 22K | n/a | May 27, 26 |
Clark Ian T Director | Acquired (grant/award) | +5K | added 31% | 22K | n/a | May 27, 26 |
Gehchan Naji Officer | Acquired (grant/award) | +18K 0.03% of company | n/a | 18K | n/a | Mar 13, 26 |
Biddle Warner Weston Officer | Acquired (grant/award) | +58K 0.09% of company | n/a | 58K | n/a | Mar 13, 26 |
Grasso Marc Officer | Acquired (grant/award) | +10K 0.02% of company | n/a | 10K | n/a | Mar 13, 26 |
Emany Sravan Kumar Director | Acquired (grant/award) | +11K 0.02% of company | n/a | 11K | n/a | Feb 24, 26 |
Miller Andrew Craig Director | Acquired (grant/award) | +11K 0.02% of company | n/a | 11K | n/a | Feb 24, 26 |
Shaw Christi Officer | Acquired (grant/award) | +54K 0.09% of company | added 100% | 71K | n/a | Jan 12, 26 |
Westlake Biopartners Opportunity Fund I, L.P. Beneficial Owner (10%) | Bought (open market) | +133K 0.2% of company | added 2.9% | 4.66M | $1000K at $7.50 | Dec 18, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on KYTX from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KYTX today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
KYTX last traded at $7.20, up 2.27% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Kyverna Therapeutics, Inc. Common Stock (KYTX) is next expected to report earnings on Wednesday, November 11, 2026, about 52 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The KYTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KYTX 64 times in the last 30 days.
KYTX (Kyverna Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $441M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KYTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$KYTX discussion
Sign in to ask a question or join the discussion.